![Byong Kim](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Byong Kim
Directeur/Membre du Conseil chez
LIPELLA PHARMACEUTICALS INC.
Fortune : - $ au 31/05/2026
Profil
Byong Kim currently works at Lipella Pharmaceuticals, Inc., as Independent Director from 2022, CytoReason Ltd., as Independent Director, and Bridge Biotherapeutics, Inc., as Director & Executive Vice President from 2016.
Dr. Kim also formerly worked at Novartis Institutes for Biomedical Research, Inc., as Associate Director, Alkermes, Inc., as Principal, and Oxford Bioscience Partners, as Entrepreneur-in-Residence.
Dr. Kim received his Masters Business Admin degree from Carnegie Mellon University, doctorate degree from The University of Texas at Austin, and undergraduate degree from the University of California, Irvine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/03/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Byong Kim
| Sociétés | Poste | Début |
|---|---|---|
| LIPELLA PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 01/03/2022 |
| PARATAXIS KOREA, INC. | Directeur/Membre du Conseil | 01/01/2016 |
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services Operates an artificial intelligence that develop computational model of the human body, accurate enough to start replacing animal and human trials in drug | Directeur/Membre du Conseil | - |
Anciens postes connus de Byong Kim
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | - |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Corporate Officer/Principal | - |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Private Equity Investor | - |
Formation de Byong Kim
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Health Technology |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lipella Pharmaceuticals, Inc.
 Lipella Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes lipid-based therapies for common bladder syndromes | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Bridge Biotherapeutics, Inc.
 Bridge Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and biological products | Health Technology |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services Operates an artificial intelligence that develop computational model of the human body, accurate enough to start replacing animal and human trials in drug | Technology Services |
